Abstract
Caffeine plays a key role in noninvasive respiratory support, easing the transition from invasive to noninvasive support, shortening the length of positive airway pressure support, and lowering BPD risk. Caffeine and aminophylline are effective in decreasing apnoea and facilitating and ventilator weaning in extremely preterm newborns. This study aims to investigate the clinical significance of caffeine and aminophylline in treating premature infants with apnea under varying conditions of oxygen (O2) delivery. The current study included 38 preterm babies with apnea who underwent caffeine or aminophylline treatment at the Al-Mahaweel General Hospital between January and December 2020; the infants were 20 boys and 18 girls, with birth weights ranging from 500 to 1,250 grams. The study came out to the result that caffeine plays a key role in noninvasive respiratory support, easing the transition from invasive to noninvasive support, shortening the length of positive airway pressure support, and lowering BPD risk. Caffeine and aminophylline both are effective in decreasing apnoea and facilitating and ventilator weaning in extremely preterm newborns. Caffeine has therapeutic advantages over aminophylline, such as better enteral absorption, a longer half-life that allows for a single daily dose, reduced side effects, and a good long-term cost/benefit ratio, making it the first choice drug for the cure of apnoea in premature neonates.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.